The presence of IDH mutations provides alternative therapeutic options including selective small molecule inhibitors (e.g. Enasidenib for IDH2 mutations and Ivosidenib for IDH1 mutations) which inhibit DNA hypermethylation and lead to delayed cancer cell growth and induction of cell differentiation [45]. Here, IDH1 is linked to cancer.